Clinical Trials - Household Contacts
-
IMPAACT 2034 - Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis
Study Location: India
Eligibility: Ages Eligible for Study: up to 17 Years (Child ) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No
Enrollment: Open
-
A5300B/I2003B/PHOENIX, Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Study Location: India
Eligibility: Men and women age greater than or equal to 18 year
Enrollment: Open